

# COVID-19 Impact on Global Targeted Drugs for Breast Cancer Market Size, Status and Forecast 2020-2026

https://marketpublishers.com/r/CE864D04DFAAEN.html

Date: July 2020 Pages: 126 Price: US\$ 3,900.00 (Single User License) ID: CE864D04DFAAEN

## Abstracts

This report focuses on the global Targeted Drugs for Breast Cancer status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Targeted Drugs for Breast Cancer development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America. The key players covered in this study

Roche
Teva
Mylan
Hikma
Hengrui Medicine
Cipla
Reliance Group
Hetero
Pfizer
Eli Lilly



#### Novartis

CANbridge

Puma Biotechnology

AstraZeneca

Chugai Pharmaceutical

Eisai

GlaxoSmithKline

**Bristol-Myers Squibb** 

Otsuka Pharmaceutical

Merck

BioMarin

Hengrui Pharmaceutical

**Beijing Biostar Technologies** 

Bayer

Market segment by Type, the product can be split into

HER-2 Targeted Drugs

CDK4/6 Inhibitors

PARP Targeted Drugs

PI3K/AKT/mTor Pathway Inhibitors



### ER Targeted Drugs

Aromatase Inhibitors

**Tubulin Inhibitors** 

**VEGF** Targeted Drugs

YTMS Targeted Drugs

Other

## Market segment by Application, split into

Hospital

Clinic

Drug Center

Other

Market segment by Regions/Countries, this report covers

North America

Europe

China

Japan

Southeast Asia

India

Central & South America



The study objectives of this report are:

To analyze global Targeted Drugs for Breast Cancer status, future forecast, growth opportunity, key market and key players.

To present the Targeted Drugs for Breast Cancer development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

To strategically profile the key players and comprehensively analyze their development plan and strategies.

To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Targeted Drugs for Breast Cancer are as follows:

History Year: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.



## Contents

## **1 REPORT OVERVIEW**

- 1.1 Study Scope
- 1.2 Key Market Segments
- 1.3 Players Covered: Ranking by Targeted Drugs for Breast Cancer Revenue
- 1.4 Market Analysis by Type
- 1.4.1 Global Targeted Drugs for Breast Cancer Market Size Growth Rate by Type: 2020 VS 2026
  - 1.4.2 HER-2 Targeted Drugs
  - 1.4.3 CDK4/6 Inhibitors
  - 1.4.4 PARP Targeted Drugs
  - 1.4.5 PI3K/AKT/mTor Pathway Inhibitors
  - 1.4.6 ER Targeted Drugs
  - 1.4.7 Aromatase Inhibitors
  - 1.4.8 Tubulin Inhibitors
  - 1.4.9 VEGF Targeted Drugs
  - 1.4.10 YTMS Targeted Drugs
  - 1.4.11 Other
- 1.5 Market by Application
- 1.5.1 Global Targeted Drugs for Breast Cancer Market Share by Application: 2020 VS 2026
  - 1.5.2 Hospital
  - 1.5.3 Clinic
  - 1.5.4 Drug Center
  - 1.5.5 Other

1.6 Coronavirus Disease 2019 (Covid-19): Targeted Drugs for Breast Cancer Industry Impact

1.6.1 How the Covid-19 is Affecting the Targeted Drugs for Breast Cancer Industry

- 1.6.1.1 Targeted Drugs for Breast Cancer Business Impact Assessment Covid-19
- 1.6.1.2 Supply Chain Challenges
- 1.6.1.3 COVID-19's Impact On Crude Oil and Refined Products

1.6.2 Market Trends and Targeted Drugs for Breast Cancer Potential Opportunities in the COVID-19 Landscape

1.6.3 Measures / Proposal against Covid-19

1.6.3.1 Government Measures to Combat Covid-19 Impact

1.6.3.2 Proposal for Targeted Drugs for Breast Cancer Players to Combat Covid-19 Impact



1.7 Study Objectives

1.8 Years Considered

## 2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Targeted Drugs for Breast Cancer Market Perspective (2015-2026)

2.2 Targeted Drugs for Breast Cancer Growth Trends by Regions

2.2.1 Targeted Drugs for Breast Cancer Market Size by Regions: 2015 VS 2020 VS 2026

2.2.2 Targeted Drugs for Breast Cancer Historic Market Share by Regions (2015-2020)

2.2.3 Targeted Drugs for Breast Cancer Forecasted Market Size by Regions (2021-2026)

- 2.3 Industry Trends and Growth Strategy
  - 2.3.1 Market Top Trends
  - 2.3.2 Market Drivers
  - 2.3.3 Market Challenges
  - 2.3.4 Porter's Five Forces Analysis
  - 2.3.5 Targeted Drugs for Breast Cancer Market Growth Strategy
- 2.3.6 Primary Interviews with Key Targeted Drugs for Breast Cancer Players (Opinion Leaders)

## **3 COMPETITION LANDSCAPE BY KEY PLAYERS**

3.1 Global Top Targeted Drugs for Breast Cancer Players by Market Size

3.1.1 Global Top Targeted Drugs for Breast Cancer Players by Revenue (2015-2020)

3.1.2 Global Targeted Drugs for Breast Cancer Revenue Market Share by Players (2015-2020)

3.1.3 Global Targeted Drugs for Breast Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

3.2 Global Targeted Drugs for Breast Cancer Market Concentration Ratio

3.2.1 Global Targeted Drugs for Breast Cancer Market Concentration Ratio (CR5 and HHI)

3.2.2 Global Top 10 and Top 5 Companies by Targeted Drugs for Breast Cancer Revenue in 2019

3.3 Targeted Drugs for Breast Cancer Key Players Head office and Area Served

3.4 Key Players Targeted Drugs for Breast Cancer Product Solution and Service

- 3.5 Date of Enter into Targeted Drugs for Breast Cancer Market
- 3.6 Mergers & Acquisitions, Expansion Plans



### 4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Targeted Drugs for Breast Cancer Historic Market Size by Type (2015-2020)4.2 Global Targeted Drugs for Breast Cancer Forecasted Market Size by Type (2021-2026)

## 5 TARGETED DRUGS FOR BREAST CANCER BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Targeted Drugs for Breast Cancer Market Size by Application (2015-2020)5.2 Global Targeted Drugs for Breast Cancer Forecasted Market Size by Application (2021-2026)

### **6 NORTH AMERICA**

6.1 North America Targeted Drugs for Breast Cancer Market Size (2015-2020)
6.2 Targeted Drugs for Breast Cancer Key Players in North America (2019-2020)
6.3 North America Targeted Drugs for Breast Cancer Market Size by Type (2015-2020)
6.4 North America Targeted Drugs for Breast Cancer Market Size by Application
(2015-2020)

## 7 EUROPE

7.1 Europe Targeted Drugs for Breast Cancer Market Size (2015-2020)

7.2 Targeted Drugs for Breast Cancer Key Players in Europe (2019-2020)

7.3 Europe Targeted Drugs for Breast Cancer Market Size by Type (2015-2020)

7.4 Europe Targeted Drugs for Breast Cancer Market Size by Application (2015-2020)

#### 8 CHINA

8.1 China Targeted Drugs for Breast Cancer Market Size (2015-2020)

- 8.2 Targeted Drugs for Breast Cancer Key Players in China (2019-2020)
- 8.3 China Targeted Drugs for Breast Cancer Market Size by Type (2015-2020)

8.4 China Targeted Drugs for Breast Cancer Market Size by Application (2015-2020)

#### 9 JAPAN

9.1 Japan Targeted Drugs for Breast Cancer Market Size (2015-2020)



- 9.2 Targeted Drugs for Breast Cancer Key Players in Japan (2019-2020)
- 9.3 Japan Targeted Drugs for Breast Cancer Market Size by Type (2015-2020)
- 9.4 Japan Targeted Drugs for Breast Cancer Market Size by Application (2015-2020)

## **10 SOUTHEAST ASIA**

10.1 Southeast Asia Targeted Drugs for Breast Cancer Market Size (2015-2020)

10.2 Targeted Drugs for Breast Cancer Key Players in Southeast Asia (2019-2020)

10.3 Southeast Asia Targeted Drugs for Breast Cancer Market Size by Type (2015-2020)

10.4 Southeast Asia Targeted Drugs for Breast Cancer Market Size by Application (2015-2020)

## 11 INDIA

11.1 India Targeted Drugs for Breast Cancer Market Size (2015-2020)

11.2 Targeted Drugs for Breast Cancer Key Players in India (2019-2020)

11.3 India Targeted Drugs for Breast Cancer Market Size by Type (2015-2020)

11.4 India Targeted Drugs for Breast Cancer Market Size by Application (2015-2020)

## 12 CENTRAL & SOUTH AMERICA

12.1 Central & South America Targeted Drugs for Breast Cancer Market Size (2015-2020)

12.2 Targeted Drugs for Breast Cancer Key Players in Central & South America (2019-2020)

12.3 Central & South America Targeted Drugs for Breast Cancer Market Size by Type (2015-2020)

12.4 Central & South America Targeted Drugs for Breast Cancer Market Size by Application (2015-2020)

## 13 KEY PLAYERS PROFILES

## 13.1 Roche

- 13.1.1 Roche Company Details
- 13.1.2 Roche Business Overview and Its Total Revenue
- 13.1.3 Roche Targeted Drugs for Breast Cancer Introduction
- 13.1.4 Roche Revenue in Targeted Drugs for Breast Cancer Business (2015-2020))
- 13.1.5 Roche Recent Development



#### 13.2 Teva

- 13.2.1 Teva Company Details
- 13.2.2 Teva Business Overview and Its Total Revenue
- 13.2.3 Teva Targeted Drugs for Breast Cancer Introduction
- 13.2.4 Teva Revenue in Targeted Drugs for Breast Cancer Business (2015-2020)
- 13.2.5 Teva Recent Development

## 13.3 Mylan

- 13.3.1 Mylan Company Details
- 13.3.2 Mylan Business Overview and Its Total Revenue
- 13.3.3 Mylan Targeted Drugs for Breast Cancer Introduction
- 13.3.4 Mylan Revenue in Targeted Drugs for Breast Cancer Business (2015-2020)
- 13.3.5 Mylan Recent Development
- 13.4 Hikma
- 13.4.1 Hikma Company Details
- 13.4.2 Hikma Business Overview and Its Total Revenue
- 13.4.3 Hikma Targeted Drugs for Breast Cancer Introduction
- 13.4.4 Hikma Revenue in Targeted Drugs for Breast Cancer Business (2015-2020)
- 13.4.5 Hikma Recent Development
- 13.5 Hengrui Medicine
  - 13.5.1 Hengrui Medicine Company Details
- 13.5.2 Hengrui Medicine Business Overview and Its Total Revenue
- 13.5.3 Hengrui Medicine Targeted Drugs for Breast Cancer Introduction
- 13.5.4 Hengrui Medicine Revenue in Targeted Drugs for Breast Cancer Business (2015-2020)
- 13.5.5 Hengrui Medicine Recent Development
- 13.6 Cipla
  - 13.6.1 Cipla Company Details
- 13.6.2 Cipla Business Overview and Its Total Revenue
- 13.6.3 Cipla Targeted Drugs for Breast Cancer Introduction
- 13.6.4 Cipla Revenue in Targeted Drugs for Breast Cancer Business (2015-2020)
- 13.6.5 Cipla Recent Development
- 13.7 Reliance Group
  - 13.7.1 Reliance Group Company Details
  - 13.7.2 Reliance Group Business Overview and Its Total Revenue
  - 13.7.3 Reliance Group Targeted Drugs for Breast Cancer Introduction
- 13.7.4 Reliance Group Revenue in Targeted Drugs for Breast Cancer Business (2015-2020)
- 13.7.5 Reliance Group Recent Development
- 13.8 Hetero



- 13.8.1 Hetero Company Details
- 13.8.2 Hetero Business Overview and Its Total Revenue
- 13.8.3 Hetero Targeted Drugs for Breast Cancer Introduction
- 13.8.4 Hetero Revenue in Targeted Drugs for Breast Cancer Business (2015-2020)
- 13.8.5 Hetero Recent Development
- 13.9 Pfizer
  - 13.9.1 Pfizer Company Details
  - 13.9.2 Pfizer Business Overview and Its Total Revenue
- 13.9.3 Pfizer Targeted Drugs for Breast Cancer Introduction
- 13.9.4 Pfizer Revenue in Targeted Drugs for Breast Cancer Business (2015-2020)
- 13.9.5 Pfizer Recent Development
- 13.10 Eli Lilly
- 13.10.1 Eli Lilly Company Details
- 13.10.2 Eli Lilly Business Overview and Its Total Revenue
- 13.10.3 Eli Lilly Targeted Drugs for Breast Cancer Introduction
- 13.10.4 Eli Lilly Revenue in Targeted Drugs for Breast Cancer Business (2015-2020)
- 13.10.5 Eli Lilly Recent Development
- 13.11 Novartis
  - 10.11.1 Novartis Company Details
  - 10.11.2 Novartis Business Overview and Its Total Revenue
  - 10.11.3 Novartis Targeted Drugs for Breast Cancer Introduction
  - 10.11.4 Novartis Revenue in Targeted Drugs for Breast Cancer Business (2015-2020)
- 10.11.5 Novartis Recent Development

13.12 CANbridge

- 10.12.1 CANbridge Company Details
- 10.12.2 CANbridge Business Overview and Its Total Revenue
- 10.12.3 CANbridge Targeted Drugs for Breast Cancer Introduction
- 10.12.4 CANbridge Revenue in Targeted Drugs for Breast Cancer Business (2015-2020)
- 10.12.5 CANbridge Recent Development
- 13.13 Puma Biotechnology
- 10.13.1 Puma Biotechnology Company Details
- 10.13.2 Puma Biotechnology Business Overview and Its Total Revenue
- 10.13.3 Puma Biotechnology Targeted Drugs for Breast Cancer Introduction
- 10.13.4 Puma Biotechnology Revenue in Targeted Drugs for Breast Cancer Business (2015-2020)
- 10.13.5 Puma Biotechnology Recent Development
- 13.14 AstraZeneca
- 10.14.1 AstraZeneca Company Details



- 10.14.2 AstraZeneca Business Overview and Its Total Revenue
- 10.14.3 AstraZeneca Targeted Drugs for Breast Cancer Introduction
- 10.14.4 AstraZeneca Revenue in Targeted Drugs for Breast Cancer Business (2015-2020)
- 10.14.5 AstraZeneca Recent Development
- 13.15 Chugai Pharmaceutical
  - 10.15.1 Chugai Pharmaceutical Company Details
  - 10.15.2 Chugai Pharmaceutical Business Overview and Its Total Revenue
- 10.15.3 Chugai Pharmaceutical Targeted Drugs for Breast Cancer Introduction
- 10.15.4 Chugai Pharmaceutical Revenue in Targeted Drugs for Breast Cancer Business (2015-2020)
- 10.15.5 Chugai Pharmaceutical Recent Development
- 13.16 Eisai
- 10.16.1 Eisai Company Details
- 10.16.2 Eisai Business Overview and Its Total Revenue
- 10.16.3 Eisai Targeted Drugs for Breast Cancer Introduction
- 10.16.4 Eisai Revenue in Targeted Drugs for Breast Cancer Business (2015-2020)
- 10.16.5 Eisai Recent Development
- 13.17 GlaxoSmithKline
  - 10.17.1 GlaxoSmithKline Company Details
- 10.17.2 GlaxoSmithKline Business Overview and Its Total Revenue
- 10.17.3 GlaxoSmithKline Targeted Drugs for Breast Cancer Introduction
- 10.17.4 GlaxoSmithKline Revenue in Targeted Drugs for Breast Cancer Business (2015-2020)
- 10.17.5 GlaxoSmithKline Recent Development
- 13.18 Bristol-Myers Squibb
  - 10.18.1 Bristol-Myers Squibb Company Details
- 10.18.2 Bristol-Myers Squibb Business Overview and Its Total Revenue
- 10.18.3 Bristol-Myers Squibb Targeted Drugs for Breast Cancer Introduction
- 10.18.4 Bristol-Myers Squibb Revenue in Targeted Drugs for Breast Cancer Business (2015-2020)
- 10.18.5 Bristol-Myers Squibb Recent Development
- 13.19 Otsuka Pharmaceutical
- 10.19.1 Otsuka Pharmaceutical Company Details
- 10.19.2 Otsuka Pharmaceutical Business Overview and Its Total Revenue
- 10.19.3 Otsuka Pharmaceutical Targeted Drugs for Breast Cancer Introduction
- 10.19.4 Otsuka Pharmaceutical Revenue in Targeted Drugs for Breast Cancer Business (2015-2020)
  - 10.19.5 Otsuka Pharmaceutical Recent Development



#### 13.20 Merck

- 10.20.1 Merck Company Details
- 10.20.2 Merck Business Overview and Its Total Revenue
- 10.20.3 Merck Targeted Drugs for Breast Cancer Introduction
- 10.20.4 Merck Revenue in Targeted Drugs for Breast Cancer Business (2015-2020)
- 10.20.5 Merck Recent Development

## 13.21 BioMarin

- 10.21.1 BioMarin Company Details
- 10.21.2 BioMarin Business Overview and Its Total Revenue
- 10.21.3 BioMarin Targeted Drugs for Breast Cancer Introduction
- 10.21.4 BioMarin Revenue in Targeted Drugs for Breast Cancer Business (2015-2020)
- 10.21.5 BioMarin Recent Development
- 13.22 Hengrui Pharmaceutical
- 10.22.1 Hengrui Pharmaceutical Company Details
- 10.22.2 Hengrui Pharmaceutical Business Overview and Its Total Revenue
- 10.22.3 Hengrui Pharmaceutical Targeted Drugs for Breast Cancer Introduction
- 10.22.4 Hengrui Pharmaceutical Revenue in Targeted Drugs for Breast Cancer Business (2015-2020)
- 10.22.5 Hengrui Pharmaceutical Recent Development
- 13.23 Beijing Biostar Technologies
  - 10.23.1 Beijing Biostar Technologies Company Details
- 10.23.2 Beijing Biostar Technologies Business Overview and Its Total Revenue
- 10.23.3 Beijing Biostar Technologies Targeted Drugs for Breast Cancer Introduction

10.23.4 Beijing Biostar Technologies Revenue in Targeted Drugs for Breast Cancer Business (2015-2020)

10.23.5 Beijing Biostar Technologies Recent Development

- 13.24 Bayer
  - 10.24.1 Bayer Company Details
- 10.24.2 Bayer Business Overview and Its Total Revenue
- 10.24.3 Bayer Targeted Drugs for Breast Cancer Introduction
- 10.24.4 Bayer Revenue in Targeted Drugs for Breast Cancer Business (2015-2020)
- 10.24.5 Bayer Recent Development

## 14 ANALYST'S VIEWPOINTS/CONCLUSIONS

## **15 APPENDIX**

- 15.1 Research Methodology
  - 15.1.1 Methodology/Research Approach



+44 20 8123 2220 info@marketpublishers.com

15.1.2 Data Source15.2 Disclaimer15.3 Author Details



## **List Of Tables**

### LIST OF TABLES

Table 1. Targeted Drugs for Breast Cancer Key Market Segments Table 2. Key Players Covered: Ranking by Targeted Drugs for Breast Cancer Revenue Table 3. Ranking of Global Top Targeted Drugs for Breast Cancer Manufacturers by Revenue (US\$ Million) in 2019 Table 4. Global Targeted Drugs for Breast Cancer Market Size Growth Rate by Type (US\$ Million): 2020 VS 2026 Table 5. Key Players of HER-2 Targeted Drugs Table 6. Key Players of CDK4/6 Inhibitors Table 7. Key Players of PARP Targeted Drugs Table 8. Key Players of PI3K/AKT/mTor Pathway Inhibitors Table 9. Key Players of ER Targeted Drugs Table 10. Key Players of Aromatase Inhibitors Table 11. Key Players of Tubulin Inhibitors Table 12. Key Players of VEGF Targeted Drugs Table 13. Key Players of YTMS Targeted Drugs Table 14. Key Players of Other Table 15. COVID-19 Impact Global Market: (Four Targeted Drugs for Breast Cancer Market Size Forecast Scenarios) Table 16. Opportunities and Trends for Targeted Drugs for Breast Cancer Players in the COVID-19 Landscape Table 17. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis Table 18. Key Regions/Countries Measures against Covid-19 Impact Table 19. Proposal for Targeted Drugs for Breast Cancer Players to Combat Covid-19 Impact Table 20. Global Targeted Drugs for Breast Cancer Market Size Growth by Application (US\$ Million): 2020 VS 2026 Table 21. Global Targeted Drugs for Breast Cancer Market Size by Regions (US\$ Million): 2020 VS 2026 Table 22. Global Targeted Drugs for Breast Cancer Market Size by Regions (2015-2020) (US\$ Million) Table 23. Global Targeted Drugs for Breast Cancer Market Share by Regions (2015 - 2020)Table 24. Global Targeted Drugs for Breast Cancer Forecasted Market Size by Regions (2021-2026) (US\$ Million)

Table 25. Global Targeted Drugs for Breast Cancer Market Share by Regions



(2021 - 2026)Table 26. Market Top Trends Table 27. Key Drivers: Impact Analysis Table 28. Key Challenges Table 29. Targeted Drugs for Breast Cancer Market Growth Strategy Table 30. Main Points Interviewed from Key Targeted Drugs for Breast Cancer Players Table 31. Global Targeted Drugs for Breast Cancer Revenue by Players (2015-2020) (Million US\$) Table 32. Global Targeted Drugs for Breast Cancer Market Share by Players (2015 - 2020)Table 33. Global Top Targeted Drugs for Breast Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Targeted Drugs for Breast Cancer as of 2019) Table 34. Global Targeted Drugs for Breast Cancer by Players Market Concentration Ratio (CR5 and HHI) Table 35. Key Players Headquarters and Area Served Table 36. Key Players Targeted Drugs for Breast Cancer Product Solution and Service Table 37. Date of Enter into Targeted Drugs for Breast Cancer Market Table 38. Mergers & Acquisitions, Expansion Plans Table 39. Global Targeted Drugs for Breast Cancer Market Size by Type (2015-2020) (Million US\$) Table 40. Global Targeted Drugs for Breast Cancer Market Size Share by Type (2015 - 2020)Table 41. Global Targeted Drugs for Breast Cancer Revenue Market Share by Type (2021 - 2026)Table 42. Global Targeted Drugs for Breast Cancer Market Size Share by Application (2015 - 2020)Table 43. Global Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) (Million US\$) Table 44. Global Targeted Drugs for Breast Cancer Market Size Share by Application (2021 - 2026)Table 45. North America Key Players Targeted Drugs for Breast Cancer Revenue (2019-2020) (Million US\$) Table 46. North America Key Players Targeted Drugs for Breast Cancer Market Share (2019-2020)Table 47. North America Targeted Drugs for Breast Cancer Market Size by Type (2015-2020) (Million US\$)

Table 48. North America Targeted Drugs for Breast Cancer Market Share by Type (2015-2020)



Table 49. North America Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) (Million US\$)

Table 50. North America Targeted Drugs for Breast Cancer Market Share by Application (2015-2020)

Table 51. Europe Key Players Targeted Drugs for Breast Cancer Revenue (2019-2020) (Million US\$)

Table 52. Europe Key Players Targeted Drugs for Breast Cancer Market Share (2019-2020)

Table 53. Europe Targeted Drugs for Breast Cancer Market Size by Type (2015-2020) (Million US\$)

Table 54. Europe Targeted Drugs for Breast Cancer Market Share by Type (2015-2020) Table 55. Europe Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) (Million US\$)

Table 56. Europe Targeted Drugs for Breast Cancer Market Share by Application(2015-2020)

Table 57. China Key Players Targeted Drugs for Breast Cancer Revenue (2019-2020) (Million US\$)

Table 58. China Key Players Targeted Drugs for Breast Cancer Market Share (2019-2020)

Table 59. China Targeted Drugs for Breast Cancer Market Size by Type (2015-2020) (Million US\$)

Table 60. China Targeted Drugs for Breast Cancer Market Share by Type (2015-2020) Table 61. China Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) (Million US\$)

Table 62. China Targeted Drugs for Breast Cancer Market Share by Application (2015-2020)

Table 63. Japan Key Players Targeted Drugs for Breast Cancer Revenue (2019-2020) (Million US\$)

Table 64. Japan Key Players Targeted Drugs for Breast Cancer Market Share (2019-2020)

Table 65. Japan Targeted Drugs for Breast Cancer Market Size by Type (2015-2020) (Million US\$)

 Table 66. Japan Targeted Drugs for Breast Cancer Market Share by Type (2015-2020)

Table 67. Japan Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) (Million US\$)

Table 68. Japan Targeted Drugs for Breast Cancer Market Share by Application (2015-2020)

Table 69. Southeast Asia Key Players Targeted Drugs for Breast Cancer Revenue (2019-2020) (Million US\$)



Table 70. Southeast Asia Key Players Targeted Drugs for Breast Cancer Market Share (2019-2020)

Table 71. Southeast Asia Targeted Drugs for Breast Cancer Market Size by Type (2015-2020) (Million US\$)

Table 72. Southeast Asia Targeted Drugs for Breast Cancer Market Share by Type (2015-2020)

Table 73. Southeast Asia Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) (Million US\$)

Table 74. Southeast Asia Targeted Drugs for Breast Cancer Market Share by Application (2015-2020)

Table 75. India Key Players Targeted Drugs for Breast Cancer Revenue (2019-2020) (Million US\$)

Table 76. India Key Players Targeted Drugs for Breast Cancer Market Share (2019-2020)

Table 77. India Targeted Drugs for Breast Cancer Market Size by Type (2015-2020) (Million US\$)

Table 78. India Targeted Drugs for Breast Cancer Market Share by Type (2015-2020) Table 79. India Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) (Million US\$)

Table 80. India Targeted Drugs for Breast Cancer Market Share by Application (2015-2020)

Table 81. Central & South America Key Players Targeted Drugs for Breast Cancer Revenue (2019-2020) (Million US\$)

Table 82. Central & South America Key Players Targeted Drugs for Breast Cancer Market Share (2019-2020)

Table 83. Central & South America Targeted Drugs for Breast Cancer Market Size by Type (2015-2020) (Million US\$)

Table 84. Central & South America Targeted Drugs for Breast Cancer Market Share by Type (2015-2020)

Table 85. Central & South America Targeted Drugs for Breast Cancer Market Size by Application (2015-2020) (Million US\$)

Table 86. Central & South America Targeted Drugs for Breast Cancer Market Share by Application (2015-2020)

Table 87. Roche Company Details

Table 88. Roche Business Overview

Table 89. Roche Product

Table 90. Roche Revenue in Targeted Drugs for Breast Cancer Business (2015-2020) (Million US\$)

Table 91. Roche Recent Development



- Table 92. Teva Company Details
- Table 93. Teva Business Overview
- Table 94. Teva Product

 Table 95. Teva Revenue in Targeted Drugs for Breast Cancer Business (2015-2020)

(Million US\$)

- Table 96. Teva Recent Development
- Table 97. Mylan Company Details
- Table 98. Mylan Business Overview
- Table 99. Mylan Product
- Table 100. Mylan Revenue in Targeted Drugs for Breast Cancer Business (2015-2020) (Million US\$)
- Table 101. Mylan Recent Development
- Table 102. Hikma Company Details
- Table 103. Hikma Business Overview
- Table 104. Hikma Product

Table 105. Hikma Revenue in Targeted Drugs for Breast Cancer Business (2015-2020) (Million US\$)

- Table 106. Hikma Recent Development
- Table 107. Hengrui Medicine Company Details
- Table 108. Hengrui Medicine Business Overview
- Table 109. Hengrui Medicine Product
- Table 110. Hengrui Medicine Revenue in Targeted Drugs for Breast Cancer Business
- (2015-2020) (Million US\$)
- Table 111. Hengrui Medicine Recent Development
- Table 112. Cipla Company Details
- Table 113. Cipla Business Overview
- Table 114. Cipla Product
- Table 115. Cipla Revenue in Targeted Drugs for Breast Cancer Business (2015-2020) (Million US\$)
- Table 116. Cipla Recent Development
- Table 117. Reliance Group Company Details
- Table 118. Reliance Group Business Overview
- Table 119. Reliance Group Product
- Table 120. Reliance Group Revenue in Targeted Drugs for Breast Cancer Business
- (2015-2020) (Million US\$)
- Table 121. Reliance Group Recent Development
- Table 122. Hetero Business Overview
- Table 123. Hetero Product
- Table 124. Hetero Company Details



Table 125. Hetero Revenue in Targeted Drugs for Breast Cancer Business (2015-2020) (Million US\$)

Table 126. Hetero Recent Development

Table 127. Pfizer Company Details

- Table 128. Pfizer Business Overview
- Table 129. Pfizer Product

Table 130. Pfizer Revenue in Targeted Drugs for Breast Cancer Business (2015-2020) (Million US\$)

- Table 131. Pfizer Recent Development
- Table 132. Eli Lilly Company Details
- Table 133. Eli Lilly Business Overview
- Table 134. Eli Lilly Product

Table 135. Eli Lilly Revenue in Targeted Drugs for Breast Cancer Business (2015-2020) (Million US\$)

- Table 136. Eli Lilly Recent Development
- Table 137. Novartis Company Details
- Table 138. Novartis Business Overview
- Table 139. Novartis Product
- Table 140. Novartis Revenue in Targeted Drugs for Breast Cancer Business
- (2015-2020) (Million US\$)
- Table 141. Novartis Recent Development
- Table 142. CANbridge Company Details
- Table 143. CANbridge Business Overview
- Table 144. CANbridge Product

Table 145. CANbridge Revenue in Targeted Drugs for Breast Cancer Business

- (2015-2020) (Million US\$)
- Table 146. CANbridge Recent Development
- Table 147. Puma Biotechnology Company Details
- Table 148. Puma Biotechnology Business Overview
- Table 149. Puma Biotechnology Product

Table 150. Puma Biotechnology Revenue in Targeted Drugs for Breast Cancer Business (2015-2020) (Million US\$)

- Table 151. Puma Biotechnology Recent Development
- Table 152. AstraZeneca Company Details
- Table 153. AstraZeneca Business Overview
- Table 154. AstraZeneca Product
- Table 155. AstraZeneca Revenue in Targeted Drugs for Breast Cancer Business

(2015-2020) (Million US\$)

 Table 156. AstraZeneca Recent Development



- Table 157. Chugai Pharmaceutical Company Details
- Table 158. Chugai Pharmaceutical Business Overview
- Table 159. Chugai Pharmaceutical Product
- Table 160. Chugai Pharmaceutical Revenue in Targeted Drugs for Breast Cancer

Business (2015-2020) (Million US\$)

- Table 161. Chugai Pharmaceutical Recent Development
- Table 162. Eisai Company Details
- Table 163. Eisai Business Overview

Table 164. Eisai Product

Table 165. Eisai Revenue in Targeted Drugs for Breast Cancer Business (2015-2020) (Million US\$)

Table 166. Eisai Recent Development

Table 167. GlaxoSmithKline Company Details

Table 168. GlaxoSmithKline Business Overview

Table 169. GlaxoSmithKline Product

Table 170. GlaxoSmithKline Revenue in Targeted Drugs for Breast Cancer Business (2015-2020) (Million US\$)

Table 171. GlaxoSmithKline Recent Development

- Table 172. Bristol-Myers Squibb Company Details
- Table 173. Bristol-Myers Squibb Business Overview

Table 174. Bristol-Myers Squibb Product

Table 175. Bristol-Myers Squibb Revenue in Targeted Drugs for Breast Cancer

Business (2015-2020) (Million US\$)

Table 176. Bristol-Myers Squibb Recent Development

Table 177. Otsuka Pharmaceutical Company Details

Table 178. Otsuka Pharmaceutical Business Overview

Table 179. Otsuka Pharmaceutical Product

Table 180. Otsuka Pharmaceutical Revenue in Targeted Drugs for Breast Cancer

Business (2015-2020) (Million US\$)

- Table 181. Otsuka Pharmaceutical Recent Development
- Table 182. Merck Company Details
- Table 183. Merck Business Overview
- Table 184. Merck Product

Table 185. Merck Revenue in Targeted Drugs for Breast Cancer Business (2015-2020) (Million US\$)

- Table 186. Merck Recent Development
- Table 187. BioMarin Company Details
- Table 188. BioMarin Business Overview
- Table 189. BioMarin Product



 Table 190. BioMarin Revenue in Targeted Drugs for Breast Cancer Business

(2015-2020) (Million US\$)

Table 191. BioMarin Recent Development

Table 192. Hengrui Pharmaceutical Company Details

Table 193. Hengrui Pharmaceutical Business Overview

Table 194. Hengrui Pharmaceutical Product

Table 195. Hengrui Pharmaceutical Revenue in Targeted Drugs for Breast Cancer

Business (2015-2020) (Million US\$)

Table 196. Hengrui Pharmaceutical Recent Development

Table 197. Beijing Biostar Technologies Company Details

Table 198. Beijing Biostar Technologies Business Overview

Table 199. Beijing Biostar Technologies Product

Table 200. Beijing Biostar Technologies Revenue in Targeted Drugs for Breast Cancer Business (2015-2020) (Million US\$)

Table 201. Beijing Biostar Technologies Recent Development

Table 202. Bayer Company Details

Table 203. Bayer Business Overview

Table 204. Bayer Product

Table 205. Bayer Revenue in Targeted Drugs for Breast Cancer Business (2015-2020) (Million US\$)

Table 206. Bayer Recent Development

 Table 207. Research Programs/Design for This Report

Table 208. Key Data Information from Secondary Sources

Table 209. Key Data Information from Primary Sources



## **List Of Figures**

### LIST OF FIGURES

Figure 1. Global Targeted Drugs for Breast Cancer Market Share by Type: 2020 VS 2026

- Figure 2. HER-2 Targeted Drugs Features
- Figure 3. CDK4/6 Inhibitors Features
- Figure 4. PARP Targeted Drugs Features
- Figure 5. PI3K/AKT/mTor Pathway Inhibitors Features
- Figure 6. ER Targeted Drugs Features
- Figure 7. Aromatase Inhibitors Features
- Figure 8. Tubulin Inhibitors Features
- Figure 9. VEGF Targeted Drugs Features
- Figure 10. YTMS Targeted Drugs Features
- Figure 11. Other Features
- Figure 12. Global Targeted Drugs for Breast Cancer Market Share by Application: 2020 VS 2026
- Figure 13. Hospital Case Studies
- Figure 14. Clinic Case Studies
- Figure 15. Drug Center Case Studies
- Figure 16. Other Case Studies
- Figure 17. Targeted Drugs for Breast Cancer Report Years Considered
- Figure 18. Global Targeted Drugs for Breast Cancer Market Size YoY Growth
- 2015-2026 (US\$ Million)

Figure 19. Global Targeted Drugs for Breast Cancer Market Share by Regions: 2020 VS 2026

Figure 20. Global Targeted Drugs for Breast Cancer Market Share by Regions (2021-2026)

- Figure 21. Porter's Five Forces Analysis
- Figure 22. Global Targeted Drugs for Breast Cancer Market Share by Players in 2019
- Figure 23. Global Top Targeted Drugs for Breast Cancer Players by Company Type

(Tier 1, Tier 2 and Tier 3) (based on the Revenue in Targeted Drugs for Breast Cancer as of 2019

Figure 24. The Top 10 and 5 Players Market Share by Targeted Drugs for Breast Cancer Revenue in 2019

Figure 25. North America Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2020) (Million US\$)

Figure 26. Europe Targeted Drugs for Breast Cancer Market Size YoY Growth



(2015-2020) (Million US\$)

Figure 27. China Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2020) (Million US\$)

Figure 28. Japan Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2020) (Million US\$)

Figure 29. Southeast Asia Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2020) (Million US\$)

Figure 30. India Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2020) (Million US\$)

Figure 31. Central & South America Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2020) (Million US\$)

Figure 32. Roche Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 33. Roche Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2015-2020)

Figure 34. Teva Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 35. Teva Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2015-2020)

Figure 36. Mylan Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 37. Mylan Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2015-2020)

Figure 38. Hikma Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 39. Hikma Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2015-2020)

Figure 40. Hengrui Medicine Total Revenue (US\$ Million): 2019 Compared with 2018 Figure 41. Hengrui Medicine Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2015-2020)

Figure 42. Cipla Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 43. Cipla Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2015-2020)

Figure 44. Reliance Group Total Revenue (US\$ Million): 2019 Compared with 2018 Figure 45. Reliance Group Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2015-2020)

Figure 46. Hetero Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 47. Hetero Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2015-2020)

Figure 48. Pfizer Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 49. Pfizer Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2015-2020)

Figure 50. Eli Lilly Total Revenue (US\$ Million): 2019 Compared with 2018



Figure 51. Eli Lilly Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2015-2020)

Figure 52. Novartis Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 53. Novartis Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2015-2020)

Figure 54. CANbridge Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 55. CANbridge Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2015-2020)

Figure 56. Puma Biotechnology Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 57. Puma Biotechnology Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2015-2020)

Figure 58. AstraZeneca Total Revenue (US\$ Million): 2019 Compared with 2018 Figure 59. AstraZeneca Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2015-2020)

Figure 60. Chugai Pharmaceutical Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 61. Chugai Pharmaceutical Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2015-2020)

Figure 62. Eisai Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 63. Eisai Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2015-2020)

Figure 64. GlaxoSmithKline Total Revenue (US\$ Million): 2019 Compared with 2018 Figure 65. GlaxoSmithKline Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2015-2020)

Figure 66. Bristol-Myers Squibb Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 67. Bristol-Myers Squibb Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2015-2020)

Figure 68. Otsuka Pharmaceutical Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 69. Otsuka Pharmaceutical Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2015-2020)

Figure 70. Merck Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 71. Merck Revenue Growth Rate in Targeted Drugs for Breast Cancer Business (2015-2020)

Figure 72. Bottom-up and Top-down Approaches for This Report

Figure 73. Data Triangulation

Figure 74. Key Executives Interviewed



### I would like to order

Product name: COVID-19 Impact on Global Targeted Drugs for Breast Cancer Market Size, Status and Forecast 2020-2026

Product link: https://marketpublishers.com/r/CE864D04DFAAEN.html

Price: US\$ 3,900.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/CE864D04DFAAEN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

\*\*All fields are required

Custumer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



COVID-19 Impact on Global Targeted Drugs for Breast Cancer Market Size, Status and Forecast 2020-2026